Aimmune Therapeutics (AIMT) Tops Q1 EPS by 10c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q1 EPS of ($0.87), $0.10 better than the analyst estimate of ($0.97).

• Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019
• Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial
• Initiation of AR201 phase 2 trial in egg allergy expected in mid-2019
• Strong balance sheet expected to fund commercialization of AR101 in the U.S. and Europe and development of pipeline

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
• Home Depot beats estimates, reaffirms fiscal 2026 guidance